News & Events

Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update

Conference call and webcast in English at 3:00 pm CEST / 09:00 am EST Successful private placement of EUR 8.2 million Strategic collaboration with MorphoSys announced in July […]

Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019

HALLE (SAALE), Germany, 22 August 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its Half Year Results for 2019 on Thursday, August 29, 2019. The […]

MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

HALLE (SAALE) and PLANEGG/MUNICH Germany, 8 July 2019: Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: […]

Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio

HALLE (SAALE), Germany, 27 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835) announced today that they have […]

Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology  

HALLE (SAALE) and MUNICH, Germany, 18 June 2019 – Vivoryon Therapeutics AG, (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), a clinical stage precision […]

Probiodrug AG becomes Vivoryon Therapeutics AG

Healthy Aging – Pioneering Innovation HALLE (SAALE), Germany, 12 June 2019 – Probiodrug AG (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), focusing on […]

Ordinary General Meeting of Shareholders of Probiodrug AG

All proposed resolutions approved with large majority   HALLE (SAALE), Germany, 29 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announces that its shareholders approved all resolutions […]

Probiodrug to attend International Conferences in June 2019

HALLE (SAALE), Germany, 22 May 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), announces that the company is scheduled to attend the following conferences:   (1) 2019 BIO […]

Probiodrug Reports First Quarter 2019 Business Update

HALLE (SAALE), Germany, 16 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announced today its first quarter business update for the period ending March 31, 2019.   The […]